10:30 AM EDT, 07/09/2025 (MT Newswires) -- Maia Biotechnology ( MAIA ) reported Wednesday the dosing of the first patient in Taiwan in the expansion of phase 2 trial for ateganosine in advanced non-small cell lung cancer.

Screening for the trial is underway in Europe and Asia, Maia said.

The expansion study evaluates ateganosine in heavily pre-treated patients in third-line NSCLC who have previously failed treatment with checkpoint inhibitors and chemotherapy, it said.

Shares were up over 7% in recent trading.

Price: 1.97, Change: +0.13, Percent Change: +7.12